CD44 Splice Variants in Neurodegenerative Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack clear evidence and effective diagnostic and therapeutic targets for neurodegenerative diseases such as Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease, particularly regarding the role of CD44 splice variants in these conditions.
Innovation Solution
Identification and utilization of specific CD44 splice variants, including novel variants, through nucleotide and amino acid sequences for diagnosing and treating neurodegenerative diseases by detecting their expression levels in biological samples and modulating their expression using antibodies, oligonucleotides, and small molecule entities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for neurodegenerative diseases, then general disease detection is possible, but diagnostic precision and identification of specific disease mechanisms are insufficient
Solution Approach 1:
The patent segments the diagnostic approach by identifying and measuring specific CD44 splice variants (such as CD44v6, CD44v10, and other variant forms) rather than using general CD44 detection. This segmentation allows for precise identification of disease-specific molecular signatures in neurodegenerative conditions, enabling differentiation between disease states and providing mechanistic insights into pathological processes.
2Measurement precision
If CD44 splice variants are targeted for diagnosis, then diagnostic accuracy improves, but detection complexity increases
Solution Approach 1:
The patent employs antibodies as intermediary molecules that specifically bind to CD44 splice variants. These antibodies serve as mediators between the complex molecular targets (splice variants) and detection systems, simplifying the detection process while maintaining high accuracy. The antibodies enable indirect detection of splice variants through immunological methods, reducing the technical complexity compared to direct molecular analysis.
3Reliability
If therapeutic targets are identified in neurodegenerative diseases, then treatment effectiveness can be improved, but current lack of clear targets limits treatment options
Solution Approach 1:
The patent identifies changes in CD44 splice variant expression patterns as key parameters for disease diagnosis and treatment monitoring. By measuring specific parameters such as the relative abundance of CD44v6, CD44v10, and other variants, the invention provides quantifiable targets for therapeutic intervention. This parameter-based approach enables both diagnostic precision and treatment effectiveness by linking molecular changes to clinical outcomes.
Data Source
AI summary
There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof.